Sun Pharmaceutical Industries announced its agreement to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited, a Mumbai-based company. According to the latest regulatory filing submitted to the National Stock Exchange of India (NSE), the deal is valued at approximately ₹271.2 crore and is expected to be completed on or before 31 July 2026. This acquisition marks a significant strategic move by Sun Pharma to bolster its product portfolio in the pharmaceutical sector.
The acquisition is valued at ₹271.2 crore and will be executed through cash consideration, with no share swap involved, as per the regulatory filing. This represents a substantial financial commitment by Sun Pharmaceutical Industries to acquire complete control of Innovcare Lifesciences. The transaction is not classified as a related party transaction, and neither the promoter nor the promoter group has any interest in Innovcare.
Innovcare Lifesciences, incorporated on 21 July 2014, is engaged in the marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products. The company reported ₹94.06 crore revenue for the financial year 2025-26, showing consistent growth over the past three years. Revenues were ₹86.09 crore in 2024-25 and ₹80.93 crore in 2023-24, demonstrating steady business expansion.
The acquisition represents a strategic investment by Sun Pharma to strengthen its product portfolio and leverage Innovcare's established presence in India to enhance its market reach and capabilities. As reported in the regulatory filing, this deal is part of Sun Pharmaceutical Industries' broader growth strategy in the pharmaceutical industry, with the company aiming to utilize Innovcare's established network to expand its market footprint in the Indian pharmaceutical and healthcare sector.
Sun Pharmaceutical Industries reported strong quarterly results for the period ended March, with profitability growing by 26% to ₹2,714 crore, which aligns with the CNBC-TV18 poll of ₹2,742 crore. The company's revenue for the quarter stood at ₹14,612 crore, representing a growth of 12.8% compared to the previous year's figure of ₹12,959 crore, marginally higher than the CNBC-TV18 poll of ₹14,528.1 crore. However, EBITDA margin for the period narrowed by 160 basis points from last year to 27.1% from 28.7%, falling short of the CNBC-TV18 poll figure of 27.8%. The company also reported a 26.24% rise in consolidated net profit to ₹2,714.03 crore in Q4 FY26 as against ₹2,149.88 crore posted in the same period year ago, with total revenue increasing 12.75% YoY to ₹14,611.79 crore in the quarter ended 31 March 2026.
